African Health Sciences
Makerere University Medical School
Vol. 20, No. 3, 2020, pp. 1259-1263
Bioline Code: hs20102
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 20, No. 3, 2020, pp. 1259-1263
© Copyright 2020 - Okidi R et al.
Prostate hyperplasia in St Mary’s Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy|
Okidi, Ronald; Opira, Cyprian; Sambo, Vanusa Da Consolação; Achola, Caroline & Ogwang, David Martin
Introduction: Prostate cancer is the second commonest cancer in men worldwide. At present, every patient with lower urinary
tract symptoms (LUTS) in St. Mary’s Hospital Lacor is undergoing prostate biopsy regardless of the prostate specific antigen
(PSA) level. We sought to determine the association between PSA and malignant prostate histology.
Methods: This was a retrospective study. Data on age, PSA, prostate volume and prostate histology reported between Jan 2012
and Dec 2019 were retrieved from St. Mary’s Hospital Lacor archive and analyzed using STATA SE/13.0.
Results: Records of 97 patients with LUTS was analyzed. The median (range) age of the patients was 71 (43-100) years. Median
(range) of prostate volume was 91.8 (8.0-360.0) cc. Overall, PSA ranged from 0.21 to 399.2 ng/ml. Prostate histology showed
3.1% acinar adenocarcinoma, 24.7% adenocarcinoma and 72.2% benign prostatic hyperplasia. The median PSA amongst patients
with malignant and non-malignant prostates were 15.8 ng/ml and 6.07 ng/ml respectively. Serum PSA level was significantly
higher in patients with malignant prostate histology (Difference of mean= 9.7; p=0.001).
Conclusion: Patients with LUTS and PSA levels of 15ng/ml or more were more likely to have malignant prostate histology.
Prostate specific antigen; Prostate cancer.